Verastem (VSTM) 10-K2015 FY Annual report

Filed: 3 Mar 16, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: ablation, abraxane, absent, abundance, Academy, Andrea, Article, attack, attrition, avelumab, barrier, blocking, buildout, buildup, capture, checkpoint, chosen, circulating, CLL, Coincident, collagen, confidence, confounding, consecutive, deficiency, delisted, delisting, DeNardo, dense, density, depletion, desmoplastic, destroy, DSMB, dying, Edinburgh, encapsulating, entail, etoposide, evade, exhaustion, extracellular, fight, gemcitabine, glioblastoma, groundbreaking, horizontally, immune, immunity, immunosuppressive, immunotherapeutic, immunotherapy, incentivizing, incurrence, inhibitory, IP, KGaA, knock, leukemic, ligand, lymphocytic, lymphoma, matrix, Mechanistic, Merck, microenvironment, mimicking, mistaken, modulate, modulating, morale, NCI, NHL, outplacement, outweigh, pan, pembrolizumab, penetrate, PI, prone, pronounced, reactivate, real, refractory, regain, regrowth, reside, retention, seldom, Sept, SITC, skin, slightly, St, stimulate, stomach, stroma, stromal, surgical, surgically, Thirteen, TIW, today, transaminase, typified, tyrosine, undertook, vague, Washington, week, workforce, xenograft

Removed: Acceleron, aching, Aldefluor, Alimta, Alnara, Alnylam, America, andin, anin, arm, aromatase, asin, Augmentin, Bactroban, Baselga, bottom, box, brain, breath, California, carboplatinum, Celectol, chairman, characteristically, chest, choice, Christopher, Chugai, cisplatinum, clothing, Columbia, complement, concentration, contaminated, converted, Council, culture, Daley, Dana, database, David, deadly, derivative, derive, developingin, deviation, diffuse, digestive, diploma, distinctive, Distinguished, drinking, driven, dull, Eli, Elliott, enrich, Entinostat, EntreMed, epidermal, ER, estrogen, EVP, experiment, extend, Farber, fashion, faster, fixed, flexibility, front, geographic, George, Granocyte, great, GSK, guided, Hamilton, Hematology, Herceptin, highest, Hospital, hypothesized, implanted, Inactivation, inInternal, input, Integrative, internally, invasion, isolating, Joseph, Kadcyla, Koch, Krug, Kuhn, latency, laundered, lenograstim, Lilly, lining, Longwood, Lovenox, LP, Manchester, Max, Medal, membership, men, merlin, mesothelial, middle, Millennium, modify, Momenta, monitored, motility, mouth, mutation, Nobel, noted, objective, occasionally, occupational, Orchestra, orin, ourin, overcome, par, partner, percentile, peritoneum, persistent, Peter, Pharmacology, Phillip, Physiology, placebo, pleura, PositionChristoph, PR, preissuance, Prize, problem, progesterone, progressed, projecting, Purdue, radiotherapy, reassessment, reclassifying, recurring, redeemable, Registry, reimburse, requiredin, residual, responsive, retroactively, reverse, Richard, Rockefeller, Rorer, Royal, Sackler, Sanofi, Schlessinger, sector, segregated, sequencing, serving, Sharp, short, shoulder, solution, spanning, split, SR, stratified, suggest, Symphony, Syndax, Tamoxifen, Taxotere, temocillin, thein, thesein, throughin, Timentin, TNBC, tract, transduction, Transplantation, treatable, twenty, Tykerb, UK, validating, variable, Velcade, venture, vertical, Vogelzang, wall, Walsh, water, Wicha, Winer, Yale, Yossi

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

VSTM similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES‑OXLEY ACT OF 2002

In connection with the Annual Report on Form 10‑K of Verastem, Inc. (the “Company”) for the period ended December 31, 2015 as filed with the Securities and Exchange Commission (the “SEC”) on the date hereof (the “Report”), the undersigned, John B. Green, CPA, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes‑Oxley Act of 2002, that to my knowledge:

(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 as amended; and

(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

		/s/ John B. Green, CPA
		John B. Green, CPA
		Chief Financial Officer

Date: March 3, 2016

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the SEC or its staff upon request.